# A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

> **NCT05509790** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 17 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** LY3484356

## Key facts

- **NCT ID:** NCT05509790
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-09
- **Primary completion:** 2024-02-18
- **Final completion:** 2026-12
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05509790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05509790, "A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05509790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*